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In mice with diet-stimulated nonalcoholic steatohepatitis,
pharmacologic activation of transcription factor Nrf2
improves glucose homeostasis and inhibits hepatic steatosis,
inﬂammation, and ﬁbrosis. Nrf2-mediated amelioration of
nonalcoholic steatohepatitis and liver ﬁbrosis involves
downregulation of lipogenic genes, induction of antioxidant
genes, and suppression of both oxidative and endoplasmic
reticulum stress.
BACKGROUND & AIMS: Nonalcoholic steatohepatitis (NASH) is
associated with oxidative stress. We surmised that pharmaco-
logic activation of NF-E2 p45-related factor 2 (Nrf2) using the
acetylenic tricyclic bis(cyano enone) TBE-31 would suppress
NASH because Nrf2 is a transcriptional master regulator of
intracellular redox homeostasis.
METHODS: Nrf2þ/þ andNrf2-/-C57BL/6micewere fed a high-fat
plus fructose (HFFr) or regular chow diet for 16 weeks or 30weeks, and then treated for the ﬁnal 6 weeks, while still being fed
the same HFFr or regular chow diets, with either TBE-31 or
dimethyl sulfoxide vehicle control. Measures of whole-body
glucose homeostasis, histologic assessment of liver, and
biochemical and molecular measurements of steatosis, endo-
plasmic reticulum (ER) stress, inﬂammation, apoptosis, ﬁbrosis,
and oxidative stress were performed in livers from these animals.
RESULTS: TBE-31 treatment reversed insulin resistance in
HFFr-fed wild-type mice, but not in HFFr-fed Nrf2-null mice.
TBE-31 treatment of HFFr-fed wild-type mice substantially
decreased liver steatosis and expression of lipid synthesis
genes, while increasing hepatic expression of fatty acid oxida-
tion and lipoprotein assembly genes. Also, TBE-31 treatment
decreased ER stress, expression of inﬂammation genes, and
markers of apoptosis, ﬁbrosis, and oxidative stress in the livers
of HFFr-fed wild-type mice. By comparison, TBE-31 did not
decrease steatosis, ER stress, lipogenesis, inﬂammation,
ﬁbrosis, or oxidative stress in livers of HFFr-fed Nrf2-null mice.
CONCLUSIONS: Pharmacologic activation of Nrf2 in mice that
had already been rendered obese and insulin resistant reversed
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against NASH and liver ﬁbrosis, effects that we principally
attribute to inhibition of ER, inﬂammatory, and oxidative stress.
(Cell Mol Gastroenterol Hepatol 2018;5:367–398; https://
doi.org/10.1016/j.jcmgh.2017.11.016)
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tance, and obesity, as well as chronic overconsumption of an
energy-dense diet containing high-fat (HF) food and
sweetened beverages that contain fructose.1 It comprises a
spectrum of phenotypes ranging from simple steatosis to
nonalcoholic steatohepatitis (NASH).2 NAFLD is a major
health concern because between 20% and 40% of adults
who consume a western-style diet have NAFLD, of which
approximately 15% suffer NASH. In some individuals, NASH
progresses to cirrhosis and hepatocellular carcinoma.3
The development of NASH entails the presence of insulin
resistance, and increases in de novo lipogenesis, inﬂamma-
tion, and oxidative stress.4,5 The relationship between simple
steatosis and NASH can be viewed as a dynamic one, with
steatosis representing successful adaptation to metabolic
stress, and NASH reﬂecting failure on the part of mitochon-
dria to adapt adequately to an increased metabolic burden,
which in turn leads to increased mitochondrial production of
reactive oxygen species.6,7 Although NASH is principally a
disease of hepatocytes, the gut and adipose tissue also
contribute to hepatic insulin resistance and inﬂammation.4
The appearance of insulin resistance, de novo lipogen-
esis, inﬂammation, and oxidative stress during the devel-
opment of NASH seems intertwined and each is linked to
endoplasmic reticulum (ER) dysfunction.4,8 Aberrant pro-
tein folding within the ER, which represents ER stress,
stimulates the unfolded protein response (UPR) through
activation of 3 pathways, controlled by inositol requiring
kinase-1a (IRE1a), activating transcription factor-6 (ATF6),
and PRK-like ER kinase (PERK), and together these initiate
an adaptive program that serves to restore proteostasis.9
However, if ER stress persists in the liver for a prolonged
period, it produces pathophysiological changes associated
with NASH. For example, chronic ER stress can result in
insulin resistance through stimulation of a pathway down-
stream of IRE1a that leads to increased serine phosphory-
lation of insulin receptor substrate-1.10 Also, persistent
activation of the UPR stimulates hepatic de novo lipogenesis
via all 3 arms of the UPR, causing increased activity of sterol
regulatory element-binding protein-1c (SREBP-1c, encoded
by SREBF1), carbohydrate-responsive element-binding pro-
tein (ChREBP, encoded by MLXIPL), the spliced variant of
X-box binding protein-1 (XBP1s), peroxisome proliferator-
activated receptor gamma (PPARg), CCAAT/enhancer-
binding protein (C/EBP) a and C/EBPb,11–13 and in turn
increased lipogenesis exacerbates insulin resistance. More-
over, chronic ER stress triggers inﬂammation via IRE1a,
resulting in stimulation of IkB kinase (IKK) and c-jun
N-terminal protein kinase 1 (JNK1) that activate nuclearfactor-kB (NF-kB) and activator protein 1 (AP-1), respec-
tively,14 events that are also linked to insulin resistance.4,8 It
may also stimulate inﬂammation via PERK by attenuating
translation of the inhibitor of NF-kB (IkB), which results in a
relative excess of NF-kB.15,16 Lastly, chronic ER stress can
initiate oxidative stress by augmenting both oxidoreductin-1
activity and release of Ca2þ from the ER, which in turn
heighten mitochondrial production of reactive oxygen spe-
cies,17 and so sensitizes the innate immune system to proin-
ﬂammatory stimuli.18 Thus, chronicERstresspromotes insulin
resistance, lipogenesis, inﬂammation, and oxidative stress.
Because oxidative stress contributes to NASH, re-
searchers have examined whether loss of NF-E2 p45-related
factor 2 (Nrf2, encoded by NFE2L2) increases susceptibility
to the disease because Nrf2 is a master regulator of cellular
redox homeostasis that orchestrates adaptation to intracel-
lular redox perturbation.19 Consistent with the view that
oxidative stress is pivotal in development of NASH,
2018 TBE-31 Inhibits Diet-Induced NASH Via Nrf2 369knockout of Nrf2 in mice profoundly predisposes to NASH
stimulated by either a methionine- and choline-deﬁcient
(MCD) diet20,21 or a HF diet.22–24 Although loss of Nrf2 in-
creases sensitivity to NASH, it is less certain whether
upregulation of Nrf2 by genetic or pharmacologic ap-
proaches decreases sensitivity to the disease. Speciﬁcally,
genetic activation of Nrf2 in mice by knockdown of its
repressor Kelch-like ECH-associated protein-1 (Keap1) has
been reported to inhibit liver steatosis and NASH caused by
an MCD diet,25,26 but genetic activation of Nrf2 in mice by
knockdown of Keap1 has also been reported to increase
NASH caused by a HF diet27 and to increase insulin resis-
tance and liver steatosis when crossed onto a Lepob/ob
background.28 Set against these seemingly discrepant
results are several studies showing that pharmacologic
activation of Nrf2 protects against diabetes and NAFLD:
these include the ﬁndings that treatment with the triterpe-
noid 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid
(CDDO)-methyl ester (bardoxolone methyl) ameliorates
diabetes and hepatic steatosis in HF-fed mice29,30 and that
treatment with CDDO-imidazole attenuates diabetes in
Leprdb/db mice.31 The possibility that treatment with Nrf2
activators after the onset of diabetes might reverse insulin
resistance along with advanced stages of NAFLD has
received little attention hitherto.
In the present study, we tested whether pharmacologic
activation of Nrf2 suppresses NASH and have examined if
this can happen after disease is manifest because this sce-
nario reﬂects the clinical situation. We therefore stimulated
NASH by feeding mice chronically with a HF diet along with
fructose-containing drinking water (called HFFr diet). After
the high-calorie regimen had been in place for 24 weeks
(Study 1), and mice exhibited impaired glucose tolerance
and hyperinsulinemia, we used the potent Nrf2 activator
TBE-3132,33 (Figure 1) to test if it could improve insulin
sensitivity and glucose homeostasis, and mitigate NASH in
the liver. Lastly, we used Nrf2-/- mice (Study 2) to demon-
strate that the beneﬁcial effects of TBE-31 in this setting
require the presence of Nrf2.Figure 1. Structure of TBE-31.Materials and Methods
Chemicals
Unless otherwise stated, these were from Sigma-Aldrich
(St. Louis, MO). The acetylenic tricyclic bis(cyano enone) com-
pound TBE-31 was synthesized as described previously.32,34Animals
Male C57BL/6 mice were purchased from Charles River
(Elphinstone, Tranent, Scotland, UK) and allowed to accli-
matize for 2 weeks before being fed speciﬁc diets. Nrf2-/-
mice,35 backcrossed over at least 7 generations onto a
C57BL/6 background, were also studied. All animal care
protocols and experimental procedures were performed in
accordance with the Animal Scientiﬁc Procedures Act
(1986) and with approval of the local University of Dundee
Animal Ethics Committee. From 8 to 10 weeks of age, the
mice were provided ad libitum either regular chow (RC;
containing 7.5% fat by energy) or a HF diet (containing 60%
fat by energy), purchased from SDS Ltd (Witham, Essex,
UK). Animals were killed by cervical dislocation or by ter-
minal anesthesia using isoﬂuorane. On sacriﬁce, livers were
removed immediately and portions rapidly snap-frozen in
liquid N2 (and subsequently stored at -80C) or ﬁxed in
formalin as described elsewhere.20
All our experiments were performed in mice on a
C57BL/6 background because this strain is widely used to
study obesity and insulin resistance.36 It is, however, well
recognized that a proportion of these mice do not become
obese when fed a HF diet, for a variety of reasons, including
failure to become diabetic and increased metabolic adap-
tation resulting in an inability to saturate the trichloroacetic
acid cycle and mitochondrial oxidative metabolism.37,38
Consistent with this previously documented characteristic
of the C57BL/6 mouse, we found a small number of animals
did not become obese when fed the HF55Fr/HF30Fr diet,
and these were segregated from the others as non-
responders, and the remaining obese mice were randomized
into 2 different treatment groups (see Results section).
To ensure rapid development of NASH in wild-type
C57BL/6 mice, the HF diet was initially provided along
with drinking water containing 55% (wt/vol) fructose (ie,
the HF55Fr diet), which was used to prime Nrf2þ/þ mice for
NASH before attenuating the rate of disease development by
placing them on the HF diet along with drinking water
containing 30% (wt/vol) fructose (ie, the standard HF30Fr
diet). The sequential provision of HF55Fr and HF30Fr diets,
given only to Nrf2þ/þ C57BL/6 mice, is described in the text
as the HF55Fr/HF30Fr diet. For dietary challenge of Nrf2-/-
mice, only the standard HF30Fr diet was provided because
they are more sensitive to NASH (when placed on a HF
diet)24: because of this innate sensitivity, we thought it
unnecessary to prime Nrf2-/- mice by placing them on a
HF55Fr diet.
To test whether pharmacologic activation of Nrf2 in-
hibits the progression of NASH, 2 experimental protocols
were adopted, with different objectives. In both cases, TBE-
31 was administered (at 5 nmol/g body weight) after in-
sulin resistance had been established, and while the animals
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was to test whether activation of Nrf2 by TBE-31 could
reverse insulin resistance and suppress NAFLD once disease
was established; the objective of Study 2 was to test
whether the ability of TBE-31 to reverse insulin resistance
and suppress NAFLD requires the presence of Nrf2. In Study
1, Nrf2þ/þ mice were initially primed for 15 weeks with the
HF55Fr diet, followed by a further 9 weeks on the standard
HF30Fr diet before treatment with TBE-31, or dimethylFigure 2. Experimentaldesign. (A, Study1). Ingroup (i),Nrf2þ/þC5
by feeding a HF55Fr diet before being transferred to the standard
number of age-matchedNrf2þ/þmicewere fedanRCdiet alongwit
24weekson either of these 2 dietary regimens,mice in group (i) and
or DMSO vehicle control, by oral gavage 3 times/week for a total of
RCdiet.Glucosehomeostasiswasmonitored inallmiceby ITT,GT
andNrf2-/-C57BL/6mice,of 8–10weeksofage,were fed thestanda
31 or DMSO for a total of 6weekswhile beingmaintained on the sam
for 10weeks,withno fructose in thedrinkingwater, beforebeing trea
maintained on the same diet. Glucose homeostasis was monitoresulfoxide (DMSO) vehicle control, 3 times a week for a total
of 6 weeks by oral gavage while still being fed the standard
HF30Fr diet (Figure 2A). In Study 2, Nrf2-/- and Nrf2þ/þ
mice were provided with the standard HF30Fr diet for 10
weeks, before being treated with TBE-31, or DMSO, for a
further 6 weeks while continuing on the same diet
(Figure 2B). In both Study 1 and Study 2, mice were
weighed weekly throughout the experiments and were kil-
led 20–24 hours after receiving the ﬁnal dose of TBE-31 or7BL/6micewereﬁrst primedover aperiodof15weeks forNASH
HF30Fr diet at the beginning of Week 16. In group (ii), an equal
h unadulterateddrinkingwater throughout. After beingplaced for
group (ii) were treatedwith either TBE-31 (5 nmol/g bodyweight)
6 weeks, while still being provided with the same HF30Fr diet or
T, andPTTat the times indicated. (B, Study2). In group (i),Nrf2þ/þ
rdHF30Frdiet for10weeksbeforebeing treatedwitheitherTBE-
ediet. In group (ii),Nrf2þ/þ andNrf2-/-micewere fed theRCdiet
tedwitheitherTBE-31orDMSOfora further 6weekswhilebeing
d in all mice by ITT and PTT at the times indicated.
2018 TBE-31 Inhibits Diet-Induced NASH Via Nrf2 371DMSO by gavage. On sacriﬁce, blood was collected from the
mice and their livers removed immediately for histologic,
biochemical, and molecular analyses.
Physiological and Clinical Chemistry
Measurements
The glucose tolerance test (GTT), insulin tolerance test
(ITT), and pyruvate tolerance test (PTT) were carried out by
intraperitoneal administration of standard doses of glucose,
insulin, or pyruvate.20,24 For Study 1, an ITT and GTT were
ﬁrst performed on the mice 1.52.5 weeks immediately
preceding treatment with TBE-31, and were repeated when
the mice had been treated for 45 weeks with TBE-31
(during Weeks 28 and 29 of Study 1). Subsequently, a sin-
gle PTT was performed on these mice during Week 30. For
Study 2, an ITT and PTT were ﬁrst performed on mice 510
days immediately preceding treatment with TBE-31, and
were repeated when they had been treated for 45 weeks
with TBE-31 (during Weeks 14 and 15 of Study 2). Blood
samples were collected via the tail vein or via cardiac
puncture. Blood glucose, triglycerides, cholesterol, and
plasma leptin and insulin were measured as described
previously.24 Fasting blood glucose and insulin levels were
measured after diet and drinking water had been with-
drawn for 5 hours. Plasma alanine aminotransferase activity
was measured using commercial kits.24
Histology
Mouse liver samples were ﬁxed in 10% neutral buffered
formaldehyde and processed for hematoxylin and eosin
(H&E) and van Gieson staining by standard methods. The
severity of liver disease in mice was evaluated histologically
on H&E-stained sections using the NAFLD activity score
(NAS)39 in a blinded fashion, in which the pathologists were
unaware of the diet, treatment group, or genotype of the
mice.
Antibodies
Antibodies against proliferating cell nuclear antigen,
binding immunoglobulin protein (BIP), protein disulﬁde
isomerase (PDI), activating transcription factor-4 (ATF4),
JNK, phospho-JNK, phospho-eukaryotic translation initiation
factor 2A (eIf2a), p58 inhibitor of the PKR kinase (p58IPK),
poly ADP ribose polymerase (PARP), caspase-3, caspase-9,
NF-kB subunits p50, p52 and p65, IkB and phospho-IKK
were purchased from Cell Signaling Technology (Danvers,
MA). Antibody against actin was from Sigma-Aldrich, anti-
body against SREBP-1c was from Millipore (Burlington, MA),
and that against ATF6 was from Santa Cruz Biotechnology
(Dallas, TX). Antibody against XBP1 was from Abcam and
that against phospho-Ire1a from ThermoFisher Scientiﬁc.
Biochemical Analyses
Frozen mouse livers (about 100 mg each) were pulver-
ized under liquid nitrogen using a pestle and mortar. The
ground material was resuspended in ice-cold RIPA lysisbuffer to which had been added protease and phosphatase
inhibitors (Roche) before homogenization. Whole-cell ly-
sates used for Western blot analyses represented the su-
pernatant fraction (15,000  g, 15 min at 4C) obtained
from the ground hepatic extracts. For the Nfkb and Srebp-1c
Western blots, nuclear and cytoplasmic fraction extracts
were prepared from frozen liver using the Pierce NE-PER kit
(ThermoScientiﬁc Life Science Research Products). Protein
concentrations were determined using bicinchoninic
acid, and assays for NAD(P)H:quinone oxidoreductase-1
(Nqo1) enzyme activity toward menadione, total gluta-
thione, reduced glutathione (GSH), oxidized glutathione
(GSSG), and malondialdehyde were performed as described
previously.20,40
Gene Expression Proﬁling
Total RNA was extracted from frozen mouse liver using
the RNeasy kit (Qiagen, Hilden, Germany), and cDNA prepared
using the Omniscript kit (Qiagen) according to the manufac-
turer’s instructions. The relative abundance of hepatic mRNA
species was measured against actin as an internal control by
TaqMan real-time polymerase chain reaction (PCR; Applied
Biosystems Prism model 7700) using commercial primer and
probe sets (Table 1), all purchased from Life Technologies.
Western Blotting
The electrophoretic resolution of proteins was per-
formed using precast NuPAGE Bis-Tris gels from Invitrogen
(ThermoFisher Scientiﬁc). Following transfer to poly-
vinylidene diﬂuoride membranes, the immunoblots were
developed with an electrochemiluminescence-based system
(Millipore) according to the manufacturer’s protocols. Film
was used to allow visualization of cross-reacting proteins;
several exposures were tested before choosing the exposure
that permitted detection of bands in all lanes. Quantiﬁcation
of the immunoblot data was conducted by measuring the
band intensities using ImageJ software, which is freely
available. In Study 1, immunoblotting was performed on
liver samples prepared from 6 different mice for each of the
diet and treatment groups. In Study 2, immunoblotting was
performed on liver samples prepared from 4 different mice
for each of the genotypes, diet, and treatment groups.
Statistics
Comparisons between the biochemical and molecular
biology results from the experimental groups were made
using Student t test or Mann-Whitney test. Data for GTT,
ITT, and PTT were analyzed by 1- or 2-way analysis of
variance with Bonferroni postcorrection. When appropriate,
repeated analysis of variance was performed with time as
subject factor. Results presented are means ± SEM. On all
occasions, data from RC-fed Nrf2þ/þ mice that had been
treated with DMSO vehicle control were used as the refer-
ence point, with signiﬁcant increases being indicated by
asterisk symbols and decreases associated with TBE-31
treatment indicated by dollar symbols, depending on the
degree of signiﬁcance (corrected P values  .05 considered
Table 1.qRT-PCR Primers and Probe Sets
Gene Protein encoded Assay ID
Acaca Acetyl-CoA carboxylase 1 Mm01304257_m1
Acly ATP Citrate Lyase Mm01302282_m1
Acot7 Acyl-CoA Thioesterase 7 Mm00460107_m1
Acox2 Acyl-CoA Oxidase 2 Mm00446408_m1
ApoB Apolipoprotein B Mm01545150_m1
Adrp Adipose differentiation related protein Mm00475794_m1
Atf4 Activating Transcription Factor 4 Mm00515325_g1
ɑSma actin, alpha 2, smooth muscle, aorta Mm00725412_s1
Bcl2 B cell leukemia/lymphoma 2 Mm00477631_m1
Cat Catalse Mm00437992_m1
Cd36 Cluster of differentiation 36 Mm01135198_m1
Ces1g Carboxylesterase 1 g Mm00491334_m1
Chop CCAAT/enhancer-binding protein
homologous protein
Mm01135937_g1
Col1a1 Collagen type I alpha 1 chain Mm00801666_g1
Cox2 Cyclooxygenase-2 Mm03294838_g1
Cpt1a Carnitine palmitoyltransferase 1A Mm01231183_m1
Dgat1 Diacylglycerol O-acyltransferase 1 Mm00515643_m1
Dgat2 Diacylglycerol O-acyltransferase 2 Mm00499536_m1
Elastase Elastase Mm00712898_m1
Fasn Fatty acid synthase Mm00662319_m1
Gclc Glutamate-cysteine ligase catalytic
subunit
Mm00802655_m1
Gclm Glutamate-cysteine ligase modiﬁer
subunit
Mm01324400_m1
Gpx2 Glutathione peroxidase 2 Mm00850074_g1
Gsta4 Glutathione S-transferase alpha 4 Mm00494803_m1
Gstm1 Glutathione S-transferase mu 1 Mm00833915_g1
Hmox1 Heme oxygenase 1 Mm00516005_m1
Ifng Interferon gamma Mm01168134_m1
Il1b Interleukin 1 beta Mm00434228_m1
Lipin1 Lipin 1 Mm00550511_m1
Lxrɑ Nuclear receptor subfamily 1 group H
member 3
Mm00443451_m1
Mcp1 Monocyte chemotactic protein 1 Mm00441242_m1
Mgpat 1-acylglycerol-3-phosphate O-
acyltransferase 9
Mm04211965_m1
Mixipl MLX interacting protein-like (also known
as Chrebp)
Mm02342723_m1
Mmp9 Matrix metallopeptidase 9 Mm00442991_m1
Mpo Myeloperoxidase Mm01298424_m1
Mttp Microsomal triglyceride transfer protein Mm01321412_g1
Nos2 Nitric oxide synthase 2 Mm00440495_g1
Nqo1 NAD(P)H:quinone oxidoreductase 1 Mm01253561_m1
Perk Eukaryotic translation initiation factor 2
alpha kinase 3
Mm00438700_m1
Pparɑ Peroxisome proliferator-activated
receptor alpha
Mm00440939_m1
Prdx6 Peroxiredoxin 6 Mm00725435_s1
Ptgr1 Prostaglandin reductase 1 Mm00482476_m1
Scad Short-chain acyl-CoA dehydrogenase Mm00431617_m1
Scd1 Stearoyl-Coenzyme A desaturase 1 Mm00772290_m1
Table 1.Continued
Gene Protein encoded Assay ID
Slc7a11 Solute carrier family 7 member 11 Mm01292536_m1
Srebf1 Sterol regulatory element binding
transcription factor 1
Mm00550338_m1
Tgfb Transforming growth factor beta 1 Mm01178820_m1
Tnfɑ Tumor necrosis factor alpha Mm00443258_m1
Txn1 Thioredoxin 1 Mm00726847_s1
Txnrd1 Thioredoxin reductase 1 Mm00443675_m1
qRT-PCR, quantitative reverse transcriptase polymerase
chain reaction.
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between data from HFFr-fed mice and other data sets are
indicated by a horizontal bar that is placed above the rele-
vant groups. Comparisons between the histology NAFLD
activity scores were made using the Kruskal-Wallis H test.
Results
TBE-31 Improves Insulin Sensitivity and
Diminishes Histologic Evidence of Nonalcoholic
Steatohepatitis and Cirrhosis
In Study 1, NASH was produced in wild-type C57BL/6
mice using the HF55Fr/HF30Fr diet. After 24 weeks on this
regimen (Figure 2A), Nrf2þ/þ mice were approximately 2.3-
fold heavier than age-matched RC-fed animals. At this time
point, 20 of the 25 HF55Fr/HF30Fr-fed mice were obese,
having gained 21.030.3 g weight over the 24-week period,
whereas the remaining 5 gained 12.116.6 g weight and
were judged to be nonobese (Figure 3A). The 5 nonobese
HF55Fr/HF30Fr-fed mice, which had not gained more
weight than the RC-fed mice over the same period, were
excluded from further study because they were considered
to be nonresponders37,38; interestingly, ITT analyses
revealed these nonresponders cleared glucose from the
blood more effectively than did the remaining 20 obese
mice, suggesting they were sensitive to insulin (Figure 3B).
Among the remaining animals, fasting blood glucose con-
centrations were greater in HF55Fr/HF30Fr-fed mice than
in RC-fed mice (Figure 3C).
ITT and GTT analyses showed the 20 obese Nrf2þ/þ
HF55Fr/HF30Fr-fed mice exhibited impaired glucose
clearance and were less responsive to insulin (measured at
22–23 weeks) than the RC-fed mice (Figure 4A and B).
Following 9 weeks on the standard HF30Fr diet (ie, starting
at the beginning of Week 25 of the HF55Fr/HF30Fr
regimen), the obese Nrf2þ/þ mice were randomly assigned
to 2 groups that were either treated with TBE-31 or DMSO
vehicle control, for 6 weeks, while continuing to be fed the
HF30Fr diet. A second ITT and GTT, performed in Weeks 4
and 5, respectively, after TBE-31 administration
commenced, showed that TBE-31-treated mice cleared
glucose more effectively than vehicle control HF55Fr/
HF30Fr-fed mice (Figure 4C and D). PTT also revealed
that TBE-31 suppressed hepatic gluconeogenesis
2018 TBE-31 Inhibits Diet-Induced NASH Via Nrf2 373(Figure 4E). The improvement in glucose homeostasis in
HF55Fr/HF30Fr-fed mice was associated with a decrease in
weight gain (Figure 5A), but because this was not accom-
panied by a signiﬁcant decrease in plasma leptin (Figure 5B)
it is unlikely to be associated with differences in hunger.
Interestingly, TBE-31 treatment decreased fasted plasma
insulin and cholesterol levels, and plasma alanine amino-
transferase activity, in HF55Fr/HF30Fr-fed mice
(Figure 5C–E).
Once the mice were killed, we ﬁrst examined whether
the 6-week treatment with TBE-31 had resulted inactivation of Nrf2. Immunoblotting of liver extracts revealed
that the abundance of Nrf2 protein was increased approxi-
mately 2-fold by the HFFr diet, and although TBE-31
treatment did not produce a signiﬁcant further increase in
Nrf2 abundance a trend was nevertheless apparent
(Figure 6A). Most importantly, examination of Nqo1 cata-
lytic activity, an enzyme that is a prototypic marker of Nrf2
transactivation activity, revealed a 1.6-fold increase in livers
of TBE-31-treated RC-fed mice and a 1.8-fold increase in
TBE-31-treated HF55Fr/HF30Fr-fed mice, each relative to
their respective DMSO-treated controls (Figure 6B). H&E
staining revealed that livers of Nrf2þ/þ mice fed the high-
calorie diet for 30 weeks, and given DMSO vehicle over
the ﬁnal 6 weeks, exhibited marked steatosis, inﬂammation,
and hepatocyte ballooning (Figure 6C), which combined to
give an average NAS of 4.9 (Figure 6D). By comparison, the
number of hepatic steatotic vesicles and extent of inﬂam-
mation and ballooning was diminished in HF55Fr/HF30Fr-
fed mice administered TBE-31 over the ﬁnal 6 weeks,
giving an average NAS of 2.9. Individual scores for fat,
inﬂammation, ﬁbrosis, and hepatocyte ballooning revealed
that TBE-31 decreased substantially hepatocyte ballooning
(P < .05) and ﬁbrosis (P < .05) (Table 2). Van Gieson
staining also revealed TBE-31 substantially diminished
ﬁbrosis in livers of HF55Fr/HF30Fr-fed mice (Figure 6E).
TBE-31 Attenuates Expression of Lipid
Metabolism Genes in Livers of HF55Fr/HF30Fr-
Fed Mice
TBE-31 treatment decreased triglyceride and cholesterol
levels in livers of Nrf2þ/þ mice fed a HF55Fr/HF30Fr diet
(Figure 7A and B). It also decreased expression of adipose
differentiation-related protein (Adrp), a marker for the
presence of lipid droplets,41 in livers of the high-calorie diet
fed Nrf2þ/þ mice (Figure 7C), which is consistent with the
steatosis observed on H&E staining of liver sections.
Because Nrf2 positively controls lipid catabolism
genes,19 we explored whether these were induced by TBE-
31 treatment and found TBE-31 increased hepatic mRNAFigure 3.Nrf2D/D mice become obese when fed the HFFr
diet, and this is associated with hyperglycemia. Nrf2þ/þ
mice were fed either the RC or the HF55Fr/HF30Fr (HFFr) diet
for 24 weeks. Before treatment with TBE-31 or DMSO con-
trol, the physiological effect of these dietary regimens was
assessed. (A) Weight gain of individual mice over the 24-week
period on the RC or HFFr diets is presented. The encircled
mice, shown at the bottom of the HFFr plot, were excluded
from the study on the basis that they failed to become
obese.36–38 (B) A comparison of insulin sensitivity (ITT at 22
weeks) of the 5 nonobese encircled unresponsive HFFr-fed
mice (triangles) with that of the 20 obese responsive HFFr-
fed mice (squares). Results are means ± SEM (n ¼ 5 or 20
mice, for nonobese and obese groups, respectively), and
signiﬁcant decreases in blood glucose in the nonobese un-
responsive mice compared with the obese responsive mice
are indicated by: $P < .05; $$P < .01; $$$P < .001. (C) The
fasting blood glucose levels of Nrf2þ/þ mice fed RC or HFFr
diets. Results are means ± SEM (n ¼ 8–12 mice per group).
Signiﬁcant increases in fasting blood glucose, relative to that
in RC-fed Nrf2þ/þ mice, are indicated by: **P < .01.
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Figure 5. TBE-31 attenuates weight gain and increases in plasma insulin, cholesterol and alanine aminotransferase in
HFFr-fed Nrf2D/Dmice. In Study 1, Nrf2þ/þ mice were killed and blood collected after 30 weeks on either the RC or HF55Fr/
HF30Fr (HFFr) diet. (A) Mean gain in body weight over the 6-week treatment period of mice on the RC or HFFr diets that were
administered either TBE-31 or the DMSO control. (B) Plasma leptin levels in RC-fed and HFFr-fed mice treated with TBE-31 or
DMSO control. (C) Plasma insulin levels in RC-fed and HFFr-fed mice treated with TBE-31 or DMSO control. (D) Plasma
cholesterol levels in RC-fed and HFFr-fed mice treated with TBE-31 or DMSO control. (E) Plasma alanine aminotransferase
activity in RC-fed and HFFr-fed mice treated with TBE-31 or DMSO control. White bars, DMSO treated; black bars, TBE-31
treated (n ¼ 8–12 mice per group). Results are means ± SEM. Signiﬁcant increases in results, relative to those in livers
from RC-fed Nrf2þ/þmice, are indicated by: *P < .05, **P < .01, ***P < .001. Signiﬁcant decreases in results as a consequence
of treatment with TBE-31, relative to HFFr-fed Nrf2þ/þ mice, are indicated by: $P < .05, $$$P < .001. ALT, alanine
aminotransferase.
Figure 4. (See previous page). TBE-31 improves insulin sensitivity in HFFr-fed Nrf2D/Dmice. (A) Insulin sensitivity (ie, ITT)
(and as % change in blood glucose) in Nrf2þ/þ mice after 22 weeks RC- (white circle) or HF55Fr/HF30Fr (HFFr)- (white square)
feeding. (B) Glucose tolerance (ie, GTT, with AUC) in Nrf2þ/þ mice after 23 weeks RC (white circle) or HFFr (white square)
feeding. (C) Insulin sensitivity (ITT) (and as % change in blood glucose) in Nrf2þ/þ mice after 28 weeks HFFr diet, and 4 weeks
DMSO (white square) or TBE-31 (black square). (D) Glucose tolerance (GTT, with AUC) in Nrf2þ/þmice after 29 weeks HFFr diet
and 5 weeks DMSO (white square) or TBE-31 (black square). (E) Pyruvate tolerance (PTT) (and as % change in blood glucose,
with AUC) in Nrf2þ/þ mice after 29.5 weeks RC diet or HFFr diet, and 5 weeks DMSO (white square) or TBE-31 (black square).
In A and B, n ¼ 20–24 mice/group: in C–E, n ¼ 6–8 mice/group. White bars, DMSO treated; black bars, TBE-31 treated. Data
are means ± SEM: *,$P < .05; **P < .01; ***P < .001. AUC, area under the curve.
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Figure 6. TBE-31 treatment increases hepatic Nrf2 activity and improves liver histology in HFFr-fed Nrf2D/D mice. On
completion of the Study 1 protocol, Nrf2þ/þ mice were killed and livers removed. (A) A representative immunoblot for Nrf2
protein in liver extracts from RC-fed or HFFr-fed mice treated with DMSO or TBE-31 (left side), with densitometric scans of
blots (right side) (n ¼ 6 biologic replicates). (B) Nqo1 catalytic activity in hepatic extracts from RC-fed and HFFr-fed mice (n ¼
8–12 mice per group). (C) Representative images for H&E staining of liver sections from RC- and HFFr-fed Nrf2þ/þmice treated
with DMSO or TBE-31 (scale bars ¼ 100 mm). (D) The NAFLD activity score39 was calculated (n ¼ 8–12 mice per group): note,
on the y-axis the score includes negative values because livers from RC-fed Nrf2þ/þ mice gave NAFLD activity scores of
essentially zero. (E) Representative images for van Gieson staining of liver sections from Nrf2þ/þ mice after 30 weeks RC or
HF55Fr/HF30Fr feeding, followed by 6 weeks DMSO or TBE-31 treatment (scale bars ¼ 100 mm). White bars, DMSO treated;
black bars, TBE-31 treated. Results are means ± SEM. Signiﬁcant increases in Nrf2 protein, Nqo1 activity, or NAFLD activity
score, relative to that in livers from RC-fed Nrf2þ/þ mice, are indicated by: *P < .05; ***P < .001. Signiﬁcant decreases in
NAFLD activity score upon treatment with TBE-31, relative to HFFr-fed Nrf2þ/þ mice, are indicated by: $P < .05.
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(Ces1g), and acetyl-CoA thioesterase 7 (Acot7) (Figure 8A).
Changes in fatty acid oxidation genes were also observed,
with the HF55Fr/HF30Fr diet increasing mRNA for peroxi-
some proliferator-activated receptor a (Ppara), and
decreasing carnitine palmitoyltransferase 1a (Cpt1a) and
short-chain acyl-CoA dehydrogenase (Scad), with TBE-31intervention raising levels of all 3 of the mRNA species
(Figure 8B).
We considered whether decreased hepatic steatosis in
HF55Fr/HF30Fr-fed mice treated with TBE-31 might
involve diminished de novo lipogenesis. Among transcrip-
tion factors that control lipid metabolism, mRNAs for
Srebp-1c and Chrebp (encoded by Srebf1 and Mlxipl,
Table 2.TBE-31 Decreases Histological Features Associated
With NASH and Cirrhosis in Livers of Mice Fed a
HFFr Diet
Parameter
Value (n)
DMSO TBE-31
NASa (maximum 8)
RC 0.091 (11) 0.182 (11)
HFFr 4.901 (8) 2.917 (8)
Steatosis component of NASb (0–3)
RC 0.0 (11) 0.0 (11)
HFFr 2.900 (8) 1.833 (8)
Inﬂammatory component of NASc (0–3)
RC 0.091 (11) 0.182 (11)
HFFr 1.300 (8) 1.000 (8)
Ballooning component of NASd (0–2)
RC 0.0 (11) 0.0 (11)
HFFr 0.700 (8) 0.0833 (8)
Fibrosis stagee (0–3)
RC 0.0 (11) 0.0 (11)
HFFr 0.727 (8) 0.167 (8)
aThe NAS-based evaluation of severity of NAFLD was found to
be signiﬁcantly higher in livers of HFFr-fed mice than in livers
of RC-fed animals (Kruskal-Wallis test; P < .0001). Livers of
mice fed the HFFr diet and treated with DMSO vehicle control
had signiﬁcantly higher NAS than those of HFFr-fed mice
treated with TBE-31 (Kruskal-Wallis H test; P < .05).
bLivers of mice fed the HFFr diet showed more steatosis
than livers of their RC-fed counterparts (Kruskal-Wallis H test;
P < .0001). No signiﬁcant difference was observed in liver
steatosis between DMSO- and TBE-31-treated mice fed on
the same diet.
cThe inﬂammatory component was signiﬁcantly higher in
livers of mice fed on the HFFr diet when compared with their
RC-fed counterparts (Kruskal-Wallis H test; P < .0001). No
signiﬁcant difference in liver inﬂammation was observed be-
tween DMSO- and TBE-31-treated mice on the same diet.
dLiver ballooning was signiﬁcantly higher in mice fed the HFFr
diet when compared with their RC-fed counterparts (Kruskal-
Wallis H test; P < .0001). Ballooning in livers of mice fed the
HFFr diet and treated with DMSO was signiﬁcantly higher
than in livers of HFFr-fed mice treated with TBE-31 (Kruskal-
Wallis H test; P < .05).
eLiver ﬁbrosis (this is not included in the NAS calculation) was
signiﬁcantly higher in mice fed the HFFr diet when compared
with their RC-fed counterparts (Kruskal-Wallis H test; P <
.0001). Fibrosis in livers of mice fed the HFFr diet and treated
with DMSO was signiﬁcantly higher than in livers of HFFr-fed
mice treated with TBE-31 (Kruskal-Wallis H test; P < .05). Figure 7. TBE-31 decreases the abundance of tri-
glycerides and cholesterol in the livers of HFFr-fed
Nrf2D/D mice. Lipids and mRNA for Adrp were measured
in livers from mice in Study 1. Triglyceride (A) and cholesterol
(B) in livers from mice on the RC diet and mice on the HF55Fr/
HF30Fr (HFFr) diet. (C) qRT-PCR for Adrp. White bars,
DMSO-treated; black bars, TBE-31treated (n ¼ 8–12 mice
per group). Results are means ± SEM. Signiﬁcant increases in
triglyceride or cholesterol levels, relative to those in livers
from RC-fed Nrf2þ/þ mice, are indicated by: *P < .05; ***P <
.001. Signiﬁcant decreases in hepatic triglyceride or choles-
terol levels, or mRNA for Adrp, resulting from treatment with
TBE-31, relative to HFFr-fed Nrf2þ/þ mice, are indicated by:
$P < .05.
2018 TBE-31 Inhibits Diet-Induced NASH Via Nrf2 377respectively) and the liver X receptor a (Lxra, also called
Nr1h3) and Xbp1s, were increased by the HF55Fr/HF30Fr
diet, and treatment of mice fed this high-calorie diet with
TBE-31 decreased their expression (Figure 8C). We also
found that mRNA for the lipogenic transcription factors
Pparg and C/ebpa were induced approximately 4.0-fold by
the HF55Fr/HF30Fr diet but this was not altered signiﬁ-
cantly by treatment with TBE-31 (data not shown). By
contrast, mRNA for C/ebpb was not signiﬁcantly changed
by either the HF5Fr/HF30Fr diet or by TBE-31 (data not
Figure 8. TBE-31 stimulates lipid catabolism and suppresses lipogenic transcription factors. On completion of Study 1,
livers were removed from Nrf2+/+ mice and portions examined for expression of lipid-associated genes and protein analyses of
the transcription factor Srebp-1c. (A) qRT-PCR for Acox2, Ces1g, and Acot7, (B) qRT-PCR for PPARa, Cpt1a, and Scad, and
(C) qRT-PCR for Srebf1, Mlxipl, Lxra, and Xbp1s (n ¼ 8–12 mice per group). (D) A representative Srebp-1c immunoblot of
cytoplasmic (cSrebp-1c) and nuclear (nSrebp-1c) protein (left side), with densitometric scans of blots (right side) (n ¼ 6 biologic
replicates).White bars, DMSO; black bars, TBE-31. Data are means ± SEM. Signiﬁcant increases in gene expression or protein
abundance, relative to that in livers from RC-fed Nrf2+/+ mice, are indicated by: *P < .05; **P < .01; ***P < .001. Signiﬁcant
decreases in gene expression or protein abundance, relative to that in livers from RC-fed Nrf2+/+ mice, are indicated by:
$P < .05; $$P < .05.
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levels of Srebp-1c protein in nuclear fractions from livers
of HF55Fr/HF30Fr-fed mice than in their RC-fed counter-
parts, and this was decreased by TBE-31 treatment
(Figure 8D). Because Srebp-1c and Xbp1s have been linked
to the UPR,12,42 their apparently coordinated decrease in
expression following treatment with TBE-31 suggests that
ER stress might be attenuated (see below).Because LXRa is regulated independently of ER
stress,43 we explored whether levels of mRNA for the
farnesoid X receptor (Fxr) and small heterodimer partner
(Shp) were altered by the diet, or by TBE-31 treatment,
because they have both been implicated in repression of
Lxra.44 Quantitative reverse transcriptase PCR (qRT-PCR)
revealed that neither Fxr nor Shp mRNA levels were
increased by the HF55Fr/HF30Fr diet, and neither was
2018 TBE-31 Inhibits Diet-Induced NASH Via Nrf2 379induced by TBE-31 treatment (data not shown). Similar
analysis of mRNA for retinoid X receptor alpha (Rxra),
which forms a heterodimer with Lxra, revealed that its
expression was also not affected by either diet or TBE-31
(data not shown).
Next, we examined whether downregulation of the
lipogenic transcription factors noted previously resulted in
decreased expression of lipid-synthesis enzymes. This
revealed the HF55Fr/HF30Fr diet increased mRNA for the
fatty acid synthesis enzymes acetyl-CoA carboxylase alpha
(Acaca), ATP citrate lyase (Acly), fatty acid synthase (Fasn),
and stearoyl-CoA desaturase-1 (Scd1), with TBE-31 dimin-
ishing substantially induction of these genes by the diet
(Figure 9A). The HF55Fr/HF30Fr diet also stimulated
modest increases in mRNA for the triglyceride synthesis
enzymes diacylglycerol acyltransferase-2 (Dgat2), lipin-1,
and mitochondrial glycerol-3-phosphate acetyltransferase
(Mgpat), with the induction of each decreased by TBE-31,
although Dgat1 was unaffected (Figure 9B). Thus TBE-31
suppresses liver steatosis, at least in part, by attenuating
dietary stimulation of expression and activation of Srepb-1c,Figure 9. TBE-31 suppresses expression of genes for lipid
porters. Expression of lipid synthesis enzymes and lipid transp
PCR for Acaca, Acly, Fasn, and Scd1. (B) qRT-PCR for Dgat
and ApoB. White bars, DMSO; black bars, TBE-31 (8–12 mice
indicated: *,$P < .05; **,$$P < .01; ***P < .001.Chrebp, Lxra, and Xbp1s, which consequently lowers
expression of lipogenic enzymes.
To assesswhether a decrease in lipid import or an increase
in lipid export contributes to the reduction in hepatic steatosis
affected by TBE-31, we measured mRNA for cluster of dif-
ferentiation 36 (Cd36), which contributes to lipid import, and
microsomal triglyceride transfer protein (Mttp) and apoli-
poprotein B (ApoB), which contribute to lipid export. This
revealed that the HF55Fr/HF30Fr diet increased Cd36mRNA
levels but that TBE-31 did not alter it (Figure 9C). By contrast,
although theHF55Fr/HF30Fr diet suppressedMttp andApoB
mRNA levels, TBE-31 increased their abundance (Figure 9C).
Collectively, these results suggest that TBE-31 probably
inﬂuences lipid transport to just a limited degree.Treatment With TBE-31 Suppresses
Endoplasmic Reticulum Stress in Livers of
HF55Fr/HF30Fr-Fed Mice
Because TBE-31 decreased expression of Srebf1 and
Xbp1s, we next explored whether TBE-31 antagonizessynthesis enzymes but increases expression of lipid ex-
orters were examined in livers of mice from Study-1. (A) qRT-
1, Dgat2, Lipin1, and Mgpat. (C) qRT-PCR for Cd36, Mttp,
per group). Data are means ± SEM. Signiﬁcant changes are
380 Sharma et al Cellular and Molecular Gastroenterology and Hepatology Vol. 5, No. 3steatosis by suppressing ER stress. Initially, we examined
the abundance of Bip and Pdi because their expression is
increased on activation of the UPR.45 Immunoblotting
showed the HF55Fr/HF30Fr diet increased Bip levels inFigure 10. TBE-31 suppresses ER stress in livers of Nrf2+/+ m
examined for changes in proteins and genes engaged in the UPR
loading control) in hepatic extracts from RC-fed and HF55Fr/HF3
densitometric scans of blots (n ¼ 6 biologic replicates). (B) Rep
and Xbp1u, p-eIf2a, and Atf4 (with actin as loading control) along
replicates). (C) qRT-PCR for Perk, Atf4, and Chop (n ¼ 8–12 m
black bars represent TBE-31. Data are means ± SEM. Signiﬁcaliver of Nrf2þ/þ mice, and that treatment with TBE-31
attenuated the increase (Figure 10A); this was not,
however, apparent for Pdi. Further immunoblotting indi-
cated that all 3 arms of the UPR were activated in liversice fed a HFFr diet. Livers from Nrf2+/+ mice in Study 1 were
. (A) Representative immunoblots of Bip and Pdi (with actin as
0Fr (HFFr)-fed mice treated with DMSO or TBE-31, along with
resentative immunoblots of Atf6 p50 and p90, p-Ire1a, Xbp1s
with densitometric scans of blots as indicated (n ¼ 6 biologic
ice per group). In all cases, white bars represent DMSO and
nt changes are indicated: *,$P < .05; **,$$P < .01; ***P < .001.
2018 TBE-31 Inhibits Diet-Induced NASH Via Nrf2 381of HF55Fr/HF30Fr-fed mice when compared with RC-fed
mice, and the abundance of these markers was decreased
by TBE-31 treatment: evidence for activation of Ire1a
was deduced from increases in phospho-Ire1a, for activa-
tion of Atf6 by increases in Atf6-p50, and for activation of
Perk by increases in phospho-eIf2a (Figure 10B). Hepatic
levels of mRNA for Atf4 (downstream of Perk) and C/ebp
homologous protein (Chop) (downstream of Perk)
were also increased by the high-calorie diet and attenuated
by TBE-31 (Figure 10C). Together, these data indicate that
consumption of the high-calorie diet stimulates ER stress
and this can be mitigated by TBE-31. Thus, alleviation
of ER stress by TBE-31 likely contributes to suppression
of hepatic steatosis by blunting induction of Srebf1 and
Xbp1s.TBE-31 Treatment of HF55Fr/HF30Fr-Fed Mice
Decreases Hepatic Inﬂammation, Apoptosis
and Fibrosis
Nrf2-target genes include those encoding enzymes that
metabolize proinﬂammatory lipid-derived reactive alde-
hydes, such as prostaglandin reductase-1 (Ptgr1) and
glutathione S-transferase Alpha-4 (Gsta4).19 HF55Fr/
HF30Fr suppressed mRNA for Ptgr1, which was recovered
by TBE-31 treatment (Figure 11A). By contrast, HF55Fr/
HF30Fr increased mRNA for Gsta4, with TBE-31 inducing it
further. Messenger RNA for other potential Nrf2-regulated
aldehyde-metabolizing enzymes were not induced by TBE-
31 (data not shown), suggesting they do not contribute to
suppression of hepatic inﬂammation.
Immunoblotting revealed marked increases in nuclear
levels of Nfkb p65, p52, and p50 proteins in livers from
HF55Fr/HF30Fr-fed mice, which were attenuated by TBE-
31 (Figure 11B). Remarkably, the dramatic increases in
hepatic nuclear Nfkb p65, p52, and p50 protein in mice fed
the high-calorie diet, and the attenuation by TBE-31 treat-
ment, were accompanied by correspondingly large de-
creases in Ikba protein and large increases in Ikka/b
phosphorylation (Figure 11B). The HF55Fr/HF30Fr
diet also increased Jnk phosphorylation, which was sup-
pressed by TBE-31 (Figure 11C). Taken together with the
data in Figure 10, these results suggest that ER stress in the
livers of HF55Fr/HF30Fr-fed mice may stimulate Nfkb-
directed transcription by decreasing translation of Ikba
(downstream of Perk) and by increasing Ikk activity
(downstream of Ire1a). Moreover, the ability of TBE-31 to
suppress ER stress in livers of HF55Fr/HF30Fr-fed mice
seems to be reﬂected in a diminution of diet-stimulated
increases in nuclear Nfkb protein and Ikk phosphorylation,
coupled with enhanced levels of Ikb protein.
Consistent with these results for Nfkb, we found the
high-calorie diet increased hepatic mRNA for the
Nfkb-targets cyclooxygenase-2 (Cox2) and nitric oxide
synthase-2 (Nos2), and to a lesser degree mRNA for Il-1b,
interferon-g (Ifng), monocyte chemotactic protein-1
(Mcp-1), and tumor necrosis factor-a (Tnfa) (Figure 11D).
Importantly, in livers of HF55Fr/HF30Fr-fed mice, TBE-31decreased mRNAs for Cox2, Nos2, Il-1b, Ifng, Tnfa, and
Mcp-1. Expression of the neutrophil markers elastase and
myeloperoxidase (Mpo) was higher in livers of HF55Fr/
HF30Fr-fed mice than RC-fed mice, and this was greatly
attenuated by TBE-31 (Figure 11E). Collectively, these data
suggest TBE-31 decreases activation of Ikk/Nfkb and Jnk
inﬂammatory pathways in livers of mice caused by chronic
consumption of the HF55Fr/HF30Fr diet, and diminishes
recruitment of neutrophils into the liver.
Cleavage of Parp, caspase-3 (Casp-3), and caspase-9
(Casp-9), which is indicative of apoptosis, was modestly
increased in livers of HF55Fr/HF30Fr-fed Nrf2þ/þmice, and
this was suppressed by TBE-31 (Figure 12A). Conversely,
mRNA for the apoptosis suppressor Bcl-2 was increased by
TBE-31 (Figure 12B). We next examined ﬁbrosis. qRT-PCR
revealed the HF55Fr/HF30Fr diet increased mRNA for
transforming growth factor beta-1 (Tgfb), a marker of he-
patic stellate cell activation, which was diminished by TBE-
31, as were the mRNAs for the ﬁbrosis markers collagen,
type I, alpha-1 (Col1a1) and alpha smooth muscle actin
(a-Sma), but not that for matrix metallopeptidase 9 (Mmp9)
(Figure 12B). These results suggest that treatment of
HF55Fr/HF30Fr-fed Nrf2þ/þ mice with TBE-31 diminishes
apoptosis, and also ﬁbrosis.
TBE-31 Treatment of Mice Fed an HF55Fr/
HF30Fr Diet Decreases Oxidative Stress
Consistent with the notion that NASH is accompanied by
oxidative stress, increases in malondialdehyde and oxidized
protein were observed in livers of HF55Fr/HF30Fr-fed
mice, and these increases were attenuated by TBE-31
treatment (Figure 13A and B). Moreover, the high-calorie
diet decreased hepatic levels of reduced glutathione (GSH)
relative to that of oxidized glutathione (GSSG), which is
indicative of a more oxidized intracellular environment,
with the relative abundance of GSH increased by TBE-31
treatment (Figure 13C). We also assessed whether the
HF55Fr/HF30 diet and TBE-31 treatment affected expres-
sion of Nrf2-target genes that contribute to antioxidant de-
fenses. This revealed that the high-calorie diet increased
hepatic mRNA for glutamate-cysteine ligase catalytic (Gclc)
and modiﬁer (Gclm) subunits, heme oxygenase-1 (Hmox1)
and solute carrier family 7 member 11 (Slc7a11), but not
Nqo1, glutathione S-transferase Mu-1 (Gstm1), glutathione
peroxidase-2 (Gpx2), thioredoxin-1 (Txn1) or thioredoxin
reductase-1 (Txnrd1), catalase (Cat), or peroxiredoxin 6
(Prdx6). However, the abundance of all these mRNA species
was increased by TBE-31 (Figure 13C), ﬁndings that suggest
TBE-31 helps restore normal redox homeostasis in livers
of HF55Fr/HF30Fr-fed mice by inducing Nrf2-regulated
antioxidant genes.
TBE-31 Requires Nrf2 to Increase Insulin
Sensitivity and Ameliorate Adverse Liver
Histology in HF30Fr-Fed Mice
Study 2 was instigated to determine whether Nrf2 is
essential for TBE-31 to improve glucose use in obese mice
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HF30Fr diet, Nrf2þ/þ mice rapidly gained weight before
treatment with TBE-31 or DMSO (Figure 14A); the Nrf2-/-
mice also gained substantial weight when placed on the
HF30Fr diet, relative to RC-fed Nrf2-/- mice, but a well-
recognized feature of the mutant mice is that they are
thinner than wild-type mice. Subsequently, however, when
HF30Fr-fed Nrf2þ/þ mice were treated with TBE-31 they
gained less weight than Nrf2þ/þ mice treated with DMSO.
This diminution of weight gain in HF30Fr-fed wild-type
mice on treatment with TBE-31 was not observed in
HF30Fr-fed Nrf2-null mice. In both wild-type and Nrf2-null
mice, the weight gain caused by the HF30Fr diet was
accompanied by increases in plasma leptin levels, but these
increases in leptin were not attenuated by TBE-31 treat-
ment (data not shown). Both wild-type and Nrf2-null mice
that had been placed on the HF30Fr diet for 9 weeks
exhibited impaired PTT and ITT. Although treatment of
HF30Fr-fed wild-type mice for 5 weeks with TBE-31
reduced glucose production (determined by PTT)
(Figure 14B) and improved insulin sensitivity (determined
by ITT) (Figure 14C), treatment of HF30Fr-fed Nrf2-/- mice
had substantially diminished beneﬁcial effects.
H&E staining of liver sections revealed that consumption
of the HF30Fr diet for 16 weeks stimulated greater steatosis
and inﬂammation in Nrf2-/- mice than in their wild-type
counterparts (Figure 15A), and that TBE-31 treatment of
mice on the HF30Fr diet decreased steatosis and inﬂam-
mation in wild-type livers, but not in Nrf2-/- livers
(Figure 15B). Histologic evaluation of steatosis, inﬂamma-
tion, and hepatocyte ballooning showed that the average
NAS in livers of Nrf2þ/þ mice was reduced from 2.2 to 1.0
by TBE-31 (Figure 15C, Table 3). By contrast, the average
NAS in livers of Nrf2-/- mice, estimated to be 3.1, was not
reduced by TBE-31. Examination of the H&E-stained sec-
tions revealed signiﬁcantly greater ﬁbrosis in Nrf2-null
livers than wild-type livers. Similarly, van Gieson staining
revealed ﬁbrosis only in livers of Nrf2-/- mice fed the
HF30Fr diet (Figure 15D).TBE-31 Requires Nrf2 to Suppress Steatosis,
Endoplasmic Reticulum Stress, Inﬂammation,
and Oxidative Stress in Livers From
HF30Fr-Fed Mice
As expected, immunoblotting showed the 6-week TBE-
31 treatment increased abundance of Nrf2 protein in
livers of wild-type mice; by contrast, Nrf2 protein was not
detected in livers of Nrf2-null mice under basal conditionsFigure 11. (See previous page). TBE-31 suppresses hepatic
inﬂammatory genes and abundance of proinﬂammatory proteins
mice from Study 1. (A) qRT-PCR for Ptgr1 and Gsta4 (8–12 mice
and p50 nuclear fraction proteins, with proliferating cell nuclear
with actin as loading control; densitometric scans of blots are s
immunoblots of p-Jnk and Jnk, with densitometric scans show
Il1b, Ifng, Nos2, Tnfa, and Mcp1 (n ¼ 8–12 per group). (E) qRT-P
white bars represent DMSO and black bars represent TBE-31. Da
< .05; **,$$P < .01; ***,$$$P < .001.or following TBE-31 treatment (Figure 16A). These Nrf2
immunoblotting data closely mirrored levels of Nqo1
enzyme activity in the same livers (Figure 16B). Collectively,
these ﬁndings conﬁrm that classic Nrf2-target genes are
downregulated and cannot be induced by TBE-31 in livers
of Nrf2-/- mice.
Although TBE-31 treatment of HF30Fr-fed Nrf2þ/þ mice
decreased total liver triglycerides and cholesterol, this was
not observed in HF30Fr-fed Nrf2-null mice (Figure 16C, D).
Similarly, TBE-31 did not decrease expression of the lipid
droplet marker protein Adrp in livers of HF30Fr-fed Nrf2-
null mice (Figure 16E). Although TBE-31 suppressed the
increase in expression of Srebf1, Lxra, and Xbp1s in livers of
Nrf2þ/þ mice fed the HF30Fr diet, it was unable to do so in
livers of HF30Fr-fed Nrf2-null mice (Figure 17A), suggesting
that the ability of TBE-31 to suppress expression of these
transcription factors is mediated by Nrf2. Consistent with
the qRT-PCR data for Srebf1, immunoblotting revealed TBE-
31 blunted the increase in nuclear Srebp-1c protein in livers
of HF30Fr-fed Nrf2þ/þ mice, but did not do so in livers of
HF30Fr-fed Nrf2-/- mice (Figure 17B). We also noted that
the decrease in mRNA for Lxra in livers of HF30Fr-fed mice
treated with TBE-31 was not associated with an obvious
reciprocal increase in mRNA for Fxr and Shp in either
Nrf2þ/þ or Nrf2-/- genotypes (data not shown), suggesting
that the Nrf2-dependent suppression of Lxra does not
involve Fxr or Shp. Surprisingly, TBE-31 decreased mRNA
for Chrebp, encoded by Mlxipl, in livers of both HF30Fr-fed
Nrf2þ/þ and Nrf2-/- mice (Figure 17A), a result that indicates
it can antagonize Chrebp through a mechanism that does
not involve Nrf2. Consistent with the qRT-PCR results for
Srebf1, Lxra, and Xbp1s, TBE-31 did not downregulate
mRNA for the fatty acid and triglyceride synthesis enzymes
Acaca, Fasn, and Dgat2 in livers of HF30Fr-fed Nrf2-/- mice
(Figure 17C). Although the HF30Fr diet increased mRNA for
the lipid importer Cd36 in livers of Nrf2þ/þ and Nrf2-/-
mice, TBE-31 had no additional effect on Cd36 expression
in livers of either Nrf2þ/þ or Nrf2-/- mice (Figure 17D).
Lastly, although TBE-31 increased mRNA levels for Mttp and
ApoB, which are involved lipoprotein assembly, in livers of
Nrf2þ/þ mice, it did not increase mRNA for these proteins in
livers of Nrf2-/- mice (Figure 17D).
Immunoblotting suggested that at least 2 arms of the
UPR were activated in livers of RC-fed Nrf2-/- mice when
compared with livers of RC-fed Nrf2þ/þ mice, as evidenced
by increases in Xbp1s (downstream of Ire1a), and Atf4
(downstream of Perk) (Figure 18). This also revealed livers
from HF30Fr-fed Nrf2þ/þ mice contained increased levels of
the ER marker proteins p-Ire1a, Xbp1s, p58IPK, p-eIf2a, andinﬂammation in HFFr-fed Nrf2+/+ mice. Expression of anti-
and proinﬂammatory genes was examined in livers of Nrf2+/+
per group). (B) Representative immunoblots of Nfkb p65, p52,
antigen as loading control, and cytoplasmic Ikba and p-Ikka/b
hown alongside (n ¼ 6 biologic replicates). (C) Representative
n adjacent (n ¼ 6 biologic replicates). (D) qRT-PCR for Cox2,
CR for Elastase and Mpo (8–12 mice per group). In all cases,
ta are means ± SEM. Signiﬁcant differences are denoted: *,$P
Figure 12. TBE-31 sup-
presses hepatic
apoptosis and ﬁbrosis in
HFFr-fed Nrf2D/D mice.
The expression of
apoptosis-associated pro-
teins and ﬁbrosis-
associated genes was
examined in livers of
Nrf2þ/þ mice from Study 1.
(A) Representative immu-
noblots of cleaved (CL)
Parp, caspase-9 (Casp-9),
and caspase-3 (Casp-3),
and actin as a loading con-
trol, along with densito-
metric scans (n¼ 6 biologic
replicates). (B) qRT-PCR
for Bcl-2, Tgfb, Col1a1,
a-Sma, and Mmp9 (8–12
mice per group). In all
cases,white bars represent
DMSO and black bars
represent TBE-31. Data are
means ± SEM. Signiﬁcant
differences are signiﬁed:
*,$P < .05; **,$$P < .01;
***P < .001.
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contrast, TBE-31 did not decrease these ER marker proteins
in livers from HF30Fr-fed Nrf2-/- mice.
Immunoblotting revealed that the HF30Fr diet stimu-
lated nuclear accumulation of Nfkb p65 and p50 in livers of
Nrf2þ/þ and Nrf2-/- mice, and that although TBE-31 could
attenuate this in livers of wild-type mice it was unable to do
so in Nrf2-/- livers (Figure 19A). qRT-PCR of mRNAs for
Cox2 and Nos2 indicated that the HF30Fr diet stimulated
expression of proinﬂammatory genes in the livers of
Nrf2þ/þ and Nrf2-/- mice but, whereas TBE-31 blunted this
increase in wild-type mice, TBE-31 was unable to do so in
the mutant mice (Figure 19B).
As anticipated, the inability of TBE-31 to suppress NASH
in Nrf2-/- mice was associated with higher levels of hepaticmalondialdehyde, oxidized protein, and GSSG than in Nrf2þ/þ
mice (Figure 19C–E) suggesting that TBE-31 did not sup-
press oxidative stress caused by the HF30Fr diet in Nrf2-/-
mice.Discussion
We have examined whether pharmacologic activation of
Nrf2 using the acetylenic tricyclic bis(cyano enone) com-
pound TBE-31 can suppress NASH in mice in which
diet-stimulated metabolic disease had already been
established, reﬂecting the situation encountered in clinical
practice. The experiments described herein reveal that
treatment of mice with TBE-31 conferred multiple meta-
bolic beneﬁts insofar as it increased whole-body insulin
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Figure 13. (See previous page). TBE-31 suppresses oxidative stress in HFFr-fed Nrf2D/D mice. The abundance of
oxidative stress-associated biomarkers and expression of antioxidant Nrf2-target genes examined in livers from Study 1.
(A) Malondialdehyde levels. (B) Oxidized protein levels shown as a representative Oxyblot, with densitometric quantiﬁcation
below. Lanes 1, 3, 5, and 7 negative controls; 2, RC-fed DMSO; 4, RC-fed TBE-31; 6, HFFr-fed DMSO; 8, HFFr-fed TBE-31.
(C) Ratio of GSH to GSSG. (D) qRT-PCR for Gclc, Gclm, Gpx2, Nqo1, Gstm1, Hmox1, Txn1, Txnrd1, Slc7a11, Catalase (Cat),
and Prdx6. In all cases, white bars represent DMSO and black bars represent TBE-31. In A, C, and D, n ¼ 8–12. In B, n ¼ 6.
Data are means ± SEM. Signiﬁcant differences are represented as: *,$P < .05; **,$$P < .01; ***,$$$P < .001.
Figure 14. TBE-31 fails to improve insulin sensitivity in HFFr-fed Nrf2-/- mice. During Study 2, physiological end-points and
glucose homeostasis were examined in wild-type and Nrf2-null mice fed an RC or HF30Fr (HFFr) diet (n ¼ 6–8 mice per group).
(A) Body weight gain of mice up until intervention at end of Week 10 (left, vertical striped bars, RC; diagonal striped bars, HFFr)
and following (Weeks 11–16) of treatment (right). (B) Glucose production (pyruvate tolerance) with AUC in Nrf2þ/þ (squares) and
Nrf2-/- (triangles) mice after 10 weeks HF30Fr diet, followed by 5 weeks treatment with DMSO (white squares and triangles) or
TBE-31 (black squares and triangles). (C) Insulin sensitivity (% change in blood glucose) in Nrf2þ/þ (squares) and Nrf2-/-
(triangles) mice after 10 weeks HF30Fr diet followed by 4 weeks with DMSO (white squares and triangles) or TBE-31 (black
squares and triangles).White bars, DMSO; black bars, TBE-31. Data are means ± SEM. Signiﬁcant changes: *P< .05; **,$$P< .01;
***,$$$P < .001. D–F, Scale bars ¼ 100 mm. AUC, area under the curve,
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Figure 15. TBE-31 does not improve NASH histology in livers of HFFr-fed Nrf2-/- mice. After sacriﬁce, livers from Nrf2þ/þ
and Nrf2-/- mice in Study 2 were removed and ﬁxed in formalin (n ¼ 6–8 mice per group). (A) Representative images for H&E
staining of mouse liver sections after 16 weeks RC- or HFFr-feeding, including treatment with DMSO during Weeks 11–16
(scale bars ¼ 100 mm). (B) Representative images for H&E staining of liver sections from Nrf2þ/þ and Nrf2-/- mice after 16
weeks RC- or HFFr-feeding including treatment with DMSO or TBE-31 during Weeks 11–16 (scale bars ¼ 100 mm). (C) The
extent of disease was assessed using the NAFLD activity score method.39 (D) Representative images for van Gieson staining
of liver sections from Nrf2þ/þ and Nrf2-/- mice after 16 weeks of HFFr-feeding and treatment with DMSO or TBE-31. White
bars, DMSO-treated; black bars, TBE-31 treated (6–8 mice per group). Results are means ± SEM. Signiﬁcant increases in
NAFLD activity score, relative to that in livers from RC-fed DMSO-treated Nrf2þ/þ mice, are indicated by: ***P < .001. The
signiﬁcant decrease in NAFLD activity score resulting from treatment with TBE-31, relative to HFFr-fed DMSO-treated Nrf2þ/þ
mice, is denoted by: $P < .05.
2018 TBE-31 Inhibits Diet-Induced NASH Via Nrf2 387sensitivity and improved glucose homeostasis (better
glucose disposal and reduced gluconeogenesis). Moreover,
within the liver, TBE-31 markedly diminished steatosis
and inﬂammation (ie, NASH, as evidenced by the NAS cal-
culations) and ﬁbrosis (which is not included in NAS cal-
culations). Most importantly, our data show that TBE-31
requires the presence of Nrf2 to produce these beneﬁcial
pleiotropic effects.Inﬂuence of Nrf2 Activation on Glucose
Homeostasis
It is known that Nrf2-/- mice are more sensitive than
Nrf2þ/þ mice to streptozotocin-induced diabetes, and that
pharmacologic activation of Nrf2 with sulforaphane (SFN)
can inhibit the development of diabetes,46,47 but it is not
known whether activation of Nrf2 in wild-type mice after
Table 3.Histological Examination Reveals That TBE-31 Does
not Decrease the Severity of Liver Fibrosis in Nrf2-null
Mice Fed a HFFr Diet
Parameter
Value (n)
Nrf2þ/þ mice Nrf2-/- mice
DMSO TBE-31 DMSO TBE-31
NASa (maximum 8)
RC 0.375 (8) 0.125 (8) 0.5 (6) 1.0 (7)
HFFr 2.125 (8) 1.0 (9) 3.167 (6) 2.8 (5)
Steatosis component of
NASb (0–3)
RC 0.125 (8) 0 (8) 0.1667 (6) 0.1429 (7)
HFFr 1.375 (8) 0.5556 (9) 1.833 (6) 1.8 (5)
Inﬂammatory component
of NASc (0–3)
RC 0.25 (8) 0.125 (8) 0.3333 (6) 0.8571 (7)
HFFr 0.75 (8) 0.4444 (9) 1.167 (6) 1 (5)
Ballooning component of
NASd (0–2)
RC 0 (8) 0 (8) 0 (6) 0 (7)
HFFr 0 (8) 0 (9) 0.1667 (6) 0 (5)
Fibrosis stage (0–3)e
RC 0.14 (8) 0.07 (8) 0.20 (6) 0.51 (7)
HFFr 0.33 (8) 0.10 (9) 0.75 (6) 0.69 (5)
aNAS was estimated to be signiﬁcantly higher in livers of HFFr-
fed mice than in livers of RC-fed animals in both genotypes
(Kruskal-Wallis test; P < .0001). DMSO-treated Nrf2þ/þ mice
fed the HFFr diet had a signiﬁcantly higher NAS than did TBE-
31-treated mice on the HFFr diet (Kruskal-Wallis H test; P <
.05). NAS estimates in livers of Nrf2-/- animals fed the HFFr diet
were higher, but not signiﬁcantly higher, than those in livers of
Nrf2þ/þ mice fed the HFFr diet (Kruskal-Wallis test; P > .05).
bLivers from mice fed the HFFr diet exhibited more steatosis
than their RC-fed counterparts in both genotypes (Kruskal-
Wallis H test; P < .0001). However, no signiﬁcant difference
in hepatic steatosis was observed between DMSO- and
TBE-31-treated mice fed the same diet.
cThe hepatic inﬂammatory component was signiﬁcantly
higher in mice fed the HFFr diet when compared with their
RC-fed counterparts (Kruskal-Wallis H test; P < .0001). No
signiﬁcant difference in inﬂammation was observed between
livers from DMSO- and TBE-31-treated mice fed on same
diet in both genotypes.
dBallooning was seen only in the liver of 1 Nrf2-/- mouse that
was fed the HFFr diet.
eLivers from mice fed the HFFr diet showed more ﬁbrosis (this
is not included in NAS calculation) when compared with mice
fed the RC diet in both genotypes. Nrf2þ/þ mice fed the HFFr
diet exhibited signiﬁcantly less hepatic ﬁbrosis when treated
with TBE-31 than did Nrf2þ/þ mice treated with DMSO
(Kruskal-Wallis H test; P < .05). Fibrosis in livers of Nrf2-/-mice
fed the HFFr diet was signiﬁcantly higher than in livers of their
wild-type counterparts (Kruskal-Wallis H test; P< .05). TBE-31
treatment had no effect on liver ﬁbrosis in Nrf2-/- mice.
388 Sharma et al Cellular and Molecular Gastroenterology and Hepatology Vol. 5, No. 3diabetes has been induced by physiological stimuli (ie,
chronic overnutrition) can mitigate disease. Uniquely, in the
present study, we have demonstrated that pharmacologic
activation of Nrf2 can reverse type 2 diabetes by performing
metabolic analyses before and after 45 weeks therapeutic
intervention with TBE-31 in adult Nrf2þ/þ mice fed a HFFrdiet, thereby providing clear evidence that the acetylenic
tricyclic bis(cyano enone) can improve glucose disposal and
insulin sensitivity. Our ﬁnding that TBE-31 treatment re-
verses insulin resistance in mice that have been fed chron-
ically an HFFr diet is consistent with a report that treatment
of 6-week-old diabetic db/db mice with the Nrf2 activator
CDDO-Im for 10 weeks increased glucose clearance and
lowered plasma insulin levels during an oral GTT.31 How-
ever, our results are at variance with a recent report that 4-
week treatment of adult C57BL/6J mice that had received a
60% HF diet for 10 weeks with the Nrf2 activator SFN
improved glucose tolerance during an intraperitoneal GTT
but did not improve insulin sensitivity.48 In the present
investigation, changes in glucose homeostasis affected by
TBE-31 were monitored in Study 1 using ITT and GTT, and
in Study 2 using ITT and PTT. None of these provide a
reference method for deﬁning insulin resistance, because
this is only achieved using hyperinsulinemic euglycemic
clamps. Therefore, further work is required to determine
whether the difference in the ability of TBE-31 and SFN to
improve insulin sensitivity is caused by methodological
factors (eg, the type of diet, duration of feeding, potency, or
pharmacokinetic properties of Nrf2 activators).
The fact that Nrf2-/- mice fed a HFFr diet became insulin
resistant (as assessed by ITT) is surprising because we have
previously reported that the knockout mice fed an HF diet
exhibit better insulin sensitivity than HF-fed Nrf2þ/þmice.24
This outcome, along with worsened NASH, displayed by
HFFr-fed Nrf2-/- mice, suggests Nrf2 plays a previously un-
recognized role in protection against fructose-driven meta-
bolic disorder. The reasons for this are not known. Possibly
overconsumption of fructose may cause insulin resistance
by increasing hepatic diacylglycerol levels and activating
protein kinase Cε.49 Clearly, this issue warrants further
investigation.Activation of Nrf2 Attenuates Hepatic
Lipid Metabolism
In the present study, Nrf2-mediated inhibition of HFFr-
stimulated liver steatosis by TBE-31 involves positive and
negative mechanisms. On the one hand, TBE-31 increased,
in a Nrf2-dependent manner, the abundance of mRNA for
proteins that limit lipid accumulation in the liver, such as
those involved in fatty acid oxidation (eg, Acox2, Ces1g,
Cpt1a, and Scad) and export of triglycerides (eg, Mttp and
ApoB). On the other hand, TBE-31 decreased, in a Nrf2-
dependent manner, mRNA for Srebp-1c, Xbp1s, and Lxra,
transcription factors that orchestrate de novo lipogenesis
and have been implicated in hepatic steatosis.49,50
Among the previously mentioned lipogenic transcription
factors, Srebp-1c and Xbp1s are integrated into the UPR and
are activated by ER stress.42 Because evidence suggests
Nrf2 marshals the expression of genes that collectively
antagonize ER stress,24 we propose that activation of Nrf2
by TBE-31 blunts ER stress caused by the HFFr diet, and this
in turn decreases the activity of Srebp-1c and Xbp1s, along
with expression of their target genes (eg, Acaca, Acly, Dgat2,
Fasn, and Scd1). Our hypothesis that TBE-31 protects
Figure 16. TBE-31 does not decrease steatosis in the livers of HFFr-fed Nrf2-/- mice. After completion of Study 2, livers
were removed from Nrf2þ/þ and Nrf2-/- mice to conﬁrm absence of Nrf2 in the knockout mouse, and for biochemical analyses.
(A, left side) Representative immunoblot of Nrf2 in livers of mice of both genotypes fed either a RC-diet or a HFFr-diet and
treated with DMSO or TBE-31. (A, right side) Densitometric scans of the immunoblots (n ¼ 4 biologic replicates). (B) Nqo1
catalytic activity in hepatic extracts from Nrf2þ/þ and Nrf2-/- mice fed RC or HFFr diets, and treated with DMSO or TBE-31. (C,
D) Triglycerides and cholesterol in livers from Nrf2þ/þ mice fed RC and HF30Fr diets are shown on the left side of the graphs,
and results from Nrf2-/- mice fed RC and HF30Fr diets are presented on the right side. (E) qRT-PCR for the lipid droplet-
associated protein Adrp. In all cases, white bars represent DMSO and black bars represent TBE-31. In A, 4 mice per group
were examined. In B–D, 6–8 mice per group. Data are means ± SEM. Signiﬁcant differences from Nrf2þ/þ control are indicated:
*,$P < .05; **P < .01; ***,$$$P < .001.
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Figure 18. TBE-31 fails to
suppress ER stress in
livers of HFFr-fed Nrf2-/-
mice. Livers were
collected from Nrf2+/+ and
Nrf2-/- mice at the end of
Study 2, and proteins and
genes involved in the UPR
were examined. Repre-
sentative immunoblots of
p-Ire1a, Xbp1s and Xbp1u,
p58IPK, p-eIf2a and Atf4
proteins, along with actin
as a loading control, are
shown at the top. Plots of
densitometric scans from
the blots are shown at the
bottom (n ¼ 4 biologic
replicates). White bars,
DMSO treated; black bars,
TBE-31 treated. Results
are means ± SEM. Signiﬁ-
cant increases relative to
that found in livers of RC-
fed Nrf2+/+ mice are indi-
cated by: *P < .05; **P <
.01; ***P < .001. Signiﬁcant
decreases relative to
HF30Fr-fed Nrf2+/+ mice
are indicated: $P < .05;
$$P < .01.
2018 TBE-31 Inhibits Diet-Induced NASH Via Nrf2 391against excessive hepatic steatosis, at least in part, by
blunting ER stress, could be likened to protection against
the toxic effect of the ER stressor tunicamycin by the Nrf2
activator 3H-1,2-dithiole-3-thione,51 or protection conferred
by knockdown of Keap1 against the ER stress-mediated
apoptotic effects of alkylating agents.52Figure 17. (See previous page). TBE-31 does not decrease
synthesis enzymes in livers of HFFr-fed Nrf2-/- mice. The ex
bolism, and their target genes, were examined in livers from Nrf
(HFFr) diet and treated with DMSO or TBE-31. (A) qRT-PCR fo
Xbp1s. (B) Representative Srebp-1c immunoblots of cytoplasmic
plots of densitometric scans on right side (n ¼ 4 biologic replic
Acly, Fasn, Scd1, and Dgat2. (D) qRT-PCR for the lipid import g
DMSO treated; black bars, TBE-31 treated. In A, C, and D, 6–
Signiﬁcant increases relative to that found in livers of RC-fed DM
***P < .001. Signiﬁcant decreases relative to HF30Fr-fed DMSOBesides downregulating Srebp-1c and Xbp1s, we found
pharmacologic activation of Nrf2 is associated with a
decrease in abundance of mRNA for Lxra. However, by
contrast with Srebp-1c and Xbp1s, Lxra is not activated by
ER stress,43 and so some other mechanism must be
involved. It is possible that the ability of Nrf2 toexpression of lipogenic transcription factors or fatty acid
pression of transcription factors associated with lipid meta-
2+/+ and Nrf2-/- mice that had been fed either a RC or HF30Fr
r the lipogenic transcription factors Srebf1, Mlxipl, Lxra and
(cSrebp-1c) and nuclear (nSrebp-1c) protein on left side, with
ates). (C) qRT-PCR for the fatty acid synthesis genes Acaca,
ene Cd36 and the export genes Mttp and ApoB. White bars,
8 mice per group. In B, n ¼ 4. Results are means ± SEM.
SO-treated Nrf2+/+ mice are indicated by: *P < .05; **P < .01;
-treated Nrf2+/+ mice are indicated: $P < .05; $$P < .01.
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Figure 20. Nrf2-dependent
mechanisms by which
TBE-31suppresses insulin
resistance, NASH and
cirrhosis. (A) The various
mechanisms by which
consumption of a high-fat
and high-fructose diet is
believed to drive hepatic
steatosis, NASH, and
cirrhosis.4,5,8 (B) The pro-
cesses by which we
envisage pharmacologic
activation of Nrf2 inhibits
and/or reverses liver disease
caused by consumption of a
diet enriched with high-fat
and high-fructose food-
stuffs. For further informa-
tion see Results and
Discussion sections. HSC,
hepatic stellate cell.
2018 TBE-31 Inhibits Diet-Induced NASH Via Nrf2 393downregulate the expression of Lxra is a consequence of
Nrf2 decreasing the levels of endogenous oxysteroids: this
reasoning is based on the fact that Lxra is a nuclear receptor
that is activated by oxysteroid ligands, and that the human
LXRa gene autoregulates itself because it contains an LXR
response element (LXRE) in its promoter region53,54; it is,
however, unclear if this mechanism is relevant to the mouse
because there is controversy about whether the putative
LXRE in the promoter region of mouse Lxra is func-
tional.55,56 An additional possibility is that activation of Nrf2
downregulates expression of Lxra because it decreases the
hepatic levels of thyroid hormone: this suggestion is based
on the report that triiodothyronine induces expression of
Lxra in mouse liver via the thyroid hormone receptor.56
Another explanation is that activation of Nrf2 antagonizesFigure 19. (See previous page). TBE-31 fails to suppress inﬂ
liver. The extent of inﬂammation and oxidative stress in livers of
(A) Representative immunoblots of hepatic nuclear levels of Nfkb
a loading control), along with densitometric scans (n ¼ 4 biolo
diets and treated with DMSO or TBE-31. (B) qRT-PCR for the Nfk
per group). (C) Malondialedehyde levels in livers from Nrf2þ/þ an
in livers of Nrf2þ/þ and Nrf2-/- mice shown as a representative O
and 7 negative controls; 2, RC-fed DMSO; 4, RC-fed TBE-31; 6,
GSH to GSSG (6–8 mice per group). In all cases, white bars repre
± SEM. Signiﬁcant differences are signiﬁed: *,$P < .05; **,$$P <Lxra activity, and hence its expression, by facilitating
inhibitory phosphorylation of Lxra at one of several Thr
residues by adenosine monophosphate-activated protein
kinase.57 An alternative possibility proposed by Kay et al44
is that activation of Nrf2 downregulates Lxra expression
because it leads to induction and deacetylation of Fxr that
results in induction of Shp protein, which in turn blunts
expression of the Lxra gene by forming a nonproductive
heterodimer with Lxra. However, this hypothesis was based
on experiments using SFN to activate Nrf2, and we think this
is unlikely in the case of TBE-31 because although expres-
sion of Shp was lower in livers of Nrf2-/- mice than those of
Nrf2þ/þ mice, the expression of Fxr did not differ in livers
from either genotype, nor was the mRNA for Shp or Fxr
inducible by TBE-31 in livers of Nrf2þ/þ mice. Clearly,ammation and oxidative stress in HFFr-fed Nrf2-/- mouse
Nrf2þ/þ and Nrf2-/- mice at the end of Study 2 was examined.
p65 and Nfkb p50 (using proliferating cell nuclear antigen as
gic replicates), from Nrf2þ/þ and Nrf2-/- mice fed RC or HFFr
b-target genes Cox2 and Nos2 from the same livers (6–8 mice
d Nrf2-/- mice (6–8 mice per group). (D) Oxidized protein levels
xyblot, with densitometric quantiﬁcation below: lanes 1, 3, 5,
HF30Fr-fed DMSO; 8, HF30Fr-fed TBE-31 (n ¼ 4). (E) Ratio of
sent DMSO and black bars represent TBE-31. Data are means
.01; ***,$$$P < .001.
Figure 20. (continued).
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which Nrf2 represses Lxra.
It remains unclear how TBE-31 antagonizes the expres-
sion of Chrebp. Most importantly, we found TBE-31 atten-
uated the expression of Chrebp in livers of Nrf2-/- mice,
indicating that the acetylenic tricyclic bis(cyano enone) ex-
erts Nrf2-independent effects. This action of TBE-31
possibly reﬂects changes in insulin sensitivity because the
abundance of Chrebp mRNA responds dramatically to
changes in insulin levels in human differentiated pre-
adipocytes.58 Further work is required to address this issue.Inﬂuence of Nrf2 Activation on Hepatic
Inﬂammation and Nonalcoholic Steatohepatitis
We found Nrf2-mediated suppression of liver inﬂamma-
tion during the development of NASH involves blunting ofactivation of AP-1 and Nfkb. It is unclear in our murine model
whether ER stress or oxidative stress is more inﬂuential in
stimulating activation of AP-1 and Nfkb by the HFFr diet, but
because both forms of stress are interrelated59,60 it is plau-
sible that pharmacologic activation of Nrf2 by TBE-31 di-
minishes activation of AP-1 and Nfkb by countering ER and
oxidative stress. TBE-31 decreased Il-1bmRNA levels, in line
with the proposal that Nrf2 inhibits transcription of the Il-1b
gene by binding to the promoter and preventing recruitment
of RNA pol II.61 Therefore, it is likely TBE-31 increases the
effectiveness of this mode of repression of inﬂammation.
Furthermore, TBE-31 likely inhibits recruitment of mono-
cytes and neutrophils into the liver because it suppressed
mRNA levels forMcp1, and for elastase andmyeloperoxidase.
The demonstration that activation of Nrf2 by TBE-31
ameliorates NASH is consistent with several earlier reports
in which pharmacologic activators of Nrf2 including
2018 TBE-31 Inhibits Diet-Induced NASH Via Nrf2 395baicalein,62 SFN,63 or Ezetimibe,64 or genetic activation of
Nrf2 by expression of a hypomorphic Keap1 allele65 or
hepatocyte-speciﬁc knockout of Keap1,66 inhibit NASH in
rodents caused by an MCD diet or an HF diet. In all these
previous experiments, however, the inducing agents were
coadministered with the MCD/HF diet, or the genetic
manipulation was constitutive, and therefore they do not
address the question of whether Nrf2 can ameliorate estab-
lished disease. Thus, our present ﬁndings add substantially to
those in the literature by showing TBE-31treatment can
reverse insulin resistance and, by implication, also NASH.
Inﬂuence of Nrf2 Activation on Liver Fibrosis
Our discovery that TBE-31 can inhibit liver ﬁbrosis in
HFFr-fed mice with NASH in an Nrf2-dependent manner is
particularly noteworthy. Speciﬁcally, we found that histologic
evidence of ﬁbrosis and expression of Col1a1 and a-Smawere
substantially diminished in HFFr-fed wild-type mice treated
with TBE-31, when compared with DMSO-treated mice.
These results are in good agreement with a previous study in
rats in which the Nrf2 activators oltipraz and NK-252 atten-
uated progression of NASH-related ﬁbrosis stimulated by a
choline-deﬁcient L-amino acid-deﬁned diet,67 but whether or
not the antiﬁbrosis effects of oltipraz and NK-252 were
mediated by Nrf2 was not addressed.
Inﬂuence of Endoplasmic Reticulum Stress and
Cirrhosis on Nrf2
Wu et al68 have demonstrated that during end-stage
liver cirrhosis in mice, hepatic Nrf2 is suppressed as a
consequence of activation of the Ire1a-Xbp1 arm of the UPR,
thereby exacerbating oxidative stress and promoting further
disease. Speciﬁcally, these workers reported that experi-
mental liver cirrhosis, caused by CCl4, resulted in increases
in Xbp1s and its downstream target Hrd1, which in turn
stimulated ubiquitylation and degradation of Nrf2, thereby
decreasing expression of Nqo1 and Gclm. In the present
study, we discovered chronic feeding of Nrf2þ/þ mice with
the HFFr diet stimulated ER stress in the liver, with clear
evidence of activation of the Xbp1 arm (Figure 10A and B).
However, HFFr-feeding had a mixed effect on expression of
hepatic Nrf2-target genes insofar as the diet increased
expression of Gclc, Gclm, Hmox1, and Slc7a11, while
decreasing the expression of Txnrd1, Cat, and Prdx6
(Figure 13D). Importantly, we found that treatment of HFFr-
fed mice with TBE-31 increased the expression of all these
Nrf2-target genes. Collectively, our ﬁndings suggest that
stimulation of ER stress by chronic consumption of an HFFr
diet is not sufﬁcient to cause Hrd1-mediated suppression of
Nrf2 that cannot be overcome by administration of TBE-31.
Further work is required to deﬁne at what stage during the
progression of NASH through to cirrhosis is Nrf2 sup-
pressed by Hrd1, and what additional environmental and/or
biochemical factors, besides just ER stress, are required.
Conclusions
This investigation shows TBE-31 provides an effective
therapeutic strategy to treat NASH through the abilityof Nrf2 to direct changes in gene expression that antago-
nize lipogenesis, ER stress, inﬂammation, oxidative stress,
and ﬁbrosis (summarized in Figure 20). Work is
now required to establish whether pharmacologic activa-
tion of Nrf2 in the human can improve metabolic
syndrome, NASH, and liver ﬁbrosis. Such clinical studies
are entirely feasible because Nrf2 activators have already
been demonstrated to improve diabetes-related
biomarkers.48References
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